News

Jefferies Takes Cautious Approach on Lufax Holdings Stock

Jefferies Takes Cautious Approach on Lufax Holdings Stock

Jefferies Holds Cautious Stance on Lufax Holdings Stock

Recently, Jefferies reinstated its coverage of Lufax Holding Ltd (NYSE: LU), assigning a Hold rating and establishing a price target of $3.20. This financial service company operates primarily within the consumer finance space in China and has recently reported third-quarter results that did not meet market expectations for both revenue and earnings.

The company is in the middle of a strategic shift, moving towards consumer finance while targeting Small Business Owners (SBO). This transition has led to an adjustment in how Lufax accounts for credit losses, now recognized upfront under a full guarantee model. Although this change aims to align with long-term objectives, it has also contributed to rising operational costs and net losses early in the transition.

Future Outlook and Expectations

Looking toward the future, Jefferies envisions that Lufax could see a return to positive loan volume growth by 2025, contingent on the successful execution of its transition strategy. However, the analysts emphasized the need for additional clarity to truly grasp Lufax’s path to restoring profitability.

Lufax has faced a number of macroeconomic challenges affecting its operations and financial performance. The current Hold rating from Jefferies signals a neutral outlook on the stock, indicating that they do not see compelling buying or selling opportunities given the existing price levels.

Recent Financial Performance

In its latest reporting, Lufax revealed mixed results for the third quarter. While the company maintained a decent asset quality and noted a drop in finance costs, it still reported a significant net loss of RMB 725 million. On a more positive note, total new loan sales for Lufax in Q3 were consistent with the previous year, at RMB 50.5 billion, reflecting an 11.7% increase from the preceding quarter. Notably, the company’s consumer finance loans experienced remarkable growth of 27.8% year-over-year, now comprising 52% of total new loans.

Despite this growth, the reinstatement of Jefferies' coverage and their Hold rating underscores the need for potential investors to remain vigilant regarding Lufax's evolving circumstances and financial stability amidst its ongoing strategic undertakings.

Market Insights

Recent insights indicate that Lufax Holding Ltd’s current market capitalization is around $2.5 billion, which positions it strategically within the consumer finance sector. Currently, Lufax trades at a low Price/Book ratio of 0.21, reinforcing the cautious sentiment surrounding the stock’s performance.

Analysts have expressed expectations of a sales decline for the current year. This aligns with the challenges identified in Jefferies’ analysis, particularly reflected in a staggering revenue drop of 35.28% over the last twelve months as of the third quarter of 2024.

Nonetheless, Lufax has exhibited surprisingly strong short-term market performance, boasting a price return of 14.68% over the last month and an impressive 38.41% increase over the past six months. This upward momentum suggests that market participants may be showing optimism regarding Lufax’s ongoing transition efforts.

Investors who seek a comprehensive understanding of Lufax's financial wellness and market standing can explore additional analytical insights. Such efforts can aid in aligning their investment strategies with the company’s future trajectory.

Frequently Asked Questions

What rating did Jefferies give to Lufax Holding Ltd?

Jefferies reinstated a Hold rating for Lufax Holding Ltd.

What is Lufax's current stock price target according to Jefferies?

Jefferies set the price target for Lufax at $3.20.

What challenges is Lufax currently facing?

Lufax has been facing increased costs and net losses due to its transition towards consumer finance.

When does Jefferies predict Lufax will return to positive loan volume growth?

Jefferies forecasts that Lufax will return to positive loan volume growth by 2025.

How has Lufax's market performance been recently?

Lufax has shown a 14.68% price return over the last month and a notable 38.41% return over the past six months.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Quantum Space Joins $185M NASA Lunar Transport Deal

Updated Category News Views 322

Quantum Space Bags a Chunk of NASA's Lunar Ambitions Alright, folks, buckle up because we're about to dive into the cosmos. Quantum Space just nabbed a sweet deal—a $185 million whopper of a contract from NASA's Moon Base Transportation program. This isn't chump change; it's a 25% slice for Quantum from the lot Arrow Science and Technology is heading. We're talking...

Continue Reading
J&J's New Study: Sjögren’s Solution Insight Sparks Debate

Updated Category News Views 174

Patient-Centric Take on Sjögren's Disease Johnson & Johnson has dropped fresh Phase 2 results on nipocalimab, reminding everyone they're at the helm of reshaping treatments for Sjögren's disease (SjD). A condition leaving about four million folks craving better days, in multiple ways, shines a light on what's gripping patients the hardest. It's hard not to sit up and...

Continue Reading
TCL's Display Future: AI Meets Screens at DTC 2026

Updated Category News Views 175

Exploring New Horizons in Display Technology There's something brewing in Wuhan: a conference that’s shaping up like a tech enthusiast’s dream. This year, it's all about the symbiosis of cutting-edge tech and dazzling visuals as TCL CSOT gears up to unveil advancements at the Global Display Tech-Ecosystem Conference (DTC) 2026. If you're wondering whether this event...

Continue Reading
Off-Broadway Play 'DUST' Raises Autism Support Funds

Updated Category News Views 337

Here's the scoop: an Off-Broadway production just did something many big hitters can't pull off. 'DUST,' a show crafted like a love letter to the American West, managed to rustle up $30,000 for young adults grappled with autism. Partnering with no less than Yale's Cultural Autism Studies and the Ed Asner Family Center, this effort hit the mark in more ways than one. An...

Continue Reading
JOYEE N01 Kicks Off Global Launch with African Orders

Updated Category News Views 296

A New Chapter for JOYEE N01 There's a moment in every company's life when it either steps boldly into the future or stumbles back into obscurity. For FAW Bestune, October 28, 2026, was one of those defining moments. On this day, they launched global mass production of the JOYEE N01 in Yancheng, China. And boy, did they pull out all the stops—you don't see this kind of...

Continue Reading
Paris Baguette Pioneers Drive-Thru in Oklahoma

Updated Category News Views 406

Tapping The Unseen Potential In Bakery Cafes Every so often a business move comes along that makes you sit up and say, "Why the hell haven't they done this before?" Paris Baguette has finally cracked that code, rolling out its first-ever drive-thru in Moore, Oklahoma. Now, imagine yourself zipping through for a croissant without leaving the comfort of your car seat. Makes...

Continue Reading
Johnson & Johnson Unveils Promising PsA Treatment Data

Updated Category News Views 235

A Game-Changer in Psoriatic Arthritis Treatment? Johnson & Johnson just tossed a headline-grabbing bone into the world of psoriatic arthritis with their new ICOTYDE results. For anyone tangled in the chronic web of psoriatic arthritis, hearing about a potential new treatment like ICOTYDE comes with cautious hope. Between stiff joints and rashy skin, sufferers are often...

Continue Reading
Historic Records Set at 2026 CNO Monumental Marathon

Updated Category News Views 317

Race to Remember: Monumental Breakthroughs In the chilly November air of Indianapolis, the 2026 CNO Financial Indianapolis Monumental Marathon wasn't just another tick on the calendar—this was a banner day for running. With record-breaking performances across every distance, we saw what happens when a community of athletes, sponsors, and volunteers hits a perfect...

Continue Reading
Invasive Procedures Don't Extend Life in Stable Heart Disease

Updated Category News Views 280

Challenging Longstanding Beliefs Today’s news from the heart research front might set a few cardiology heads spinning. We’ve got big-time findings out of the ISCHEMIA-EXTEND study, throwing more weight on the evidence pile that early invasive heart procedures for patients with stable coronary artery disease don’t actually extend your life. Managing care with a blend...

Continue Reading
Boston STEM Expo Sparks Young Minds in Engineering

Updated Category News Views 165

If you really want to light up a kid's imagination, throw them into a room full of science experiments and let 'em have at it. That's exactly what happened at the recent Society of Women Engineers' Innovation Expo in Boston's Seaport District. The place was buzzing, and not just because of all the engineering gadgets on display—it was the energy of young minds...

Continue Reading

Top 5 Most Recently Viewed Articles

The Rise of Mycoplasma Testing: Future Growth and Trends

Updated Category News Views 102

Insights into the Growth of the Mycoplasma Testing Market The mycoplasma testing market is expected to balloon to USD 2.49 billion in the next few years. This impressive growth stems largely from the increasing use of cell culture techniques within biopharmaceutical research and development. As researchers and companies adopt these advanced methods, the demand for...

Continue Reading
Investors Urged to Examine Claims Against Toronto-Dominion Bank

Updated Category News Views 65

Faruqi & Faruqi Investigates Toronto-Dominion Bank Faruqi & Faruqi, LLP, a prominent national securities law firm, is currently investigating potential claims on behalf of investors who have suffered significant financial losses from their investments in The Toronto-Dominion Bank (NYSE: TD). The firm is reaching out to investors who experienced losses exceeding $100,000,...

Continue Reading
Heifer International Advocates for Farmer Support Amidst Crisis

Updated Category News Views 403

Heifer International Advocates for Farmer Support Amid Climate Crisis Heifer International is calling for urgent action to assist smallholder farmers affected by the extreme weather patterns brought on by climate change. The recent impact of Tropical Depression Sara highlights the vulnerability of agricultural communities across Central America, prompting the organization...

Continue Reading
Mitsubishi Tanabe Pharma Unveils RADICAVA ORS Insights at NASP

Updated Category News Views 135

Mitsubishi Tanabe Pharma America Unveils Data on RADICAVA ORS Mitsubishi Tanabe Pharma America, Inc. (MTPA) is thrilled to share vital information regarding their innovative product, RADICAVA ORS (edaravone), at an upcoming event designed for specialized pharmacy professionals. This presentation aims at enhancing the understanding of it’s application in managing...

Continue Reading
Warren Buffett's Coca-Cola Dividend Strategy: A Love Affair

Updated Category News Views 593

Warren Buffett's Love for Coca-Cola Warren Buffett, a legendary investor, is set to receive a staggering $776 million in dividends from Coca-Cola. This immense wealth from his investment in Coca-Cola illustrates the power of dividends in wealth accumulation. Buffett's investment journey with Coca-Cola has not only been fruitful financially but has also created a personal...

Continue Reading